Previous 10 | Next 10 |
PALO ALTO, Calif., March 23, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has completed submission to the U.S. F...
Eiger BioPharmaceuticals (NASDAQ: EIGR ): Q4 GAAP EPS of -$0.69 beats by $0.13 . More news on: Eiger BioPharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
PALO ALTO, Calif. , March 13, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for the fourth quarter and full year 2019...
Man is the only animal that blushes - or needs to ." - Mark Twain Today, we take a look at a small ' Tier 4 ' developmental firm named Eiger BioPharmaceuticals (EIGR) . There also has been some small insider buying in this concern in January meriting a 'deep dive'. A full investment an...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
PALO ALTO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment o...
PALO ALTO, Calif. , Jan. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today updated on progress across its...
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
Eiger BioPharmaceuticals (NASDAQ: EIGR ) initiates the rolling submission of its U.S. marketing application seeking approval of lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and progeroid laminopathies. More news on: Eiger BioPharmaceuticals, Inc...
PALO ALTO, Calif. , Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has ini...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...